Vincent S. Gallicchio has 45 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Dr. Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. His passion for research, a high value placed on excellence, a strong reputation as an esteemed collaborator, and a tenacious desire to see a better therapies for human diseases brought to market speak to his overall character.


Over the years his direction leading a research team produced more than 170 peer-reviewed publications, 32 book chapters, several text books, countless number of invited presentations nationally and internationally, and fourteen United States and one international patents. Dr. Gallicchio has secured in excess of $23 million dollars in research funding from various public and private funding agencies including several foundations and many pharmaceutical companies. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio serves as a Clinical Laboratory Director. He holds lab directorship certification from the South Carolina Department of Health & Environmental Control (DHEC) . He also serves as a consultant to Minerals Resources International, Inc., Logan, UT related to the health benefits of trace elements.


Gallicchio earned his Ph.D. in Experimental Hematology at New York University Medical Center and completed fellowships in hematology (Sloan Kettering Institute for Cancer Research and University of Connecticut Health Center). He was awarded a diploma in internal medicine from “Vasile Goldis” University of Arad Medical School (Romania). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, the International Federation of Biomedical Laboratory Science, and currently serves as Vice President of the Educational and Research Centers in Trace Elements operated under the auspice of UNESCO. He is a Fellow of the Association of Clinical Scientists, the Association of Schools of Allied Health Professions, and the Royal Society of the Arts (RSA). In 2003, at the 200th anniversary RSA celebration, because of his long-standing effort to educate English biomedical laboratory science students, Dr. Gallicchio was recognized by Her Majesty, Queen Elizabeth II.


Personalized medicine (PM) is a model that proposes the customization of healthcare - with medical decisions, practices, and/or products being tailored to the individual patient. Use of genomic information plays a major role in certain aspects of PM. The term was first coined in the context of genetics (though it has since broadened to encompass all sorts of personalization measures). To distinguish from the context in which medicine has always been inherently "personal" to each patient, PM commonly denotes the use of technology or discovery enabling a level of personalization not previously feasible or practical. Advances in medical and human genetics have enabled a more detailed understanding of the impact of genetics in diagnosis, treatment and prognosis of human disease. Large collaborative research projects such as the human genome project have laid the groundwork for the understanding the role of genes in normal human development including physiology revealing single nucleotide polymorphisms (SNPs) account for the genetic variability between individuals. This information has made possible the use of genome association studies (GWAS) to examine genetic variation and thus understand the risk for many common diseases. A number of topics have emerged that have targeted personalized medicine they are: pharmacogenomics, proteomics and metabolomics. For example, the management of cancer identified the presence of genes associated with the induction of a number of human cancers. This list has grown in significance amplified recently with the actions made in personal health by the actress Angelina Jolie. PM also has identified a number of notable concerns and opportunities. One such concern is the individual cost of PM for those individuals who do not have personalized health care insurance. Legislation in the form of the Genomics and Personalized Medicine Act has been introduced in the Congress of the United States to address issues involving scientific barriers, adverse market pressures and regulatory obstacles. Importantly, the passing of the Affordable Care Act and its affirmation by the Supreme Court of the United States will allow the utility of PM to continue in the U.S. Finally, in order to educate future physicians the advent of PM is influencing medical education with the development of sub- specialties in PM by a growing number of medical schools in the United States. The transition to PM is proceeding even as experts continue to debate whether does this new information actually improve health care? This dialogue will continue here at Personalized Medicine 2015 Valencia.